Company Overview and News


Add CLVS
to your dashboard

Headline News

U.S. Biotech/Pharma Sector Daily Observations Letter: January 22, 2018

10h seekingalpha
S&P 500 index was up 0.81% and could reach above 2950 before we see a meaningful pullback. It is the longest stretch now without a 5% pullback in history, so some caution is warranted. (160-0)

AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan

2018-01-22 zacks
AstraZeneca (AZN - Free Report) and partner Merck (MRK - Free Report) announced that the Japanese Ministry of Health, Labour and Welfare has granted approval to its PARP inhibitor, Lynparza, as a maintenance therapy for relapsed ovarian cancer, irrespective of BRCA mutation status in patients who have responded to their last platinum-based chemotherapy. (85-0)

U.S. Biotech/Pharma Sector Daily Observations Letter: Jan. 18, 2018

2018-01-19 seekingalpha
U.S. hospital systems to partner in order to create their own generic drugs business to save rising generic drug costs. (366-1)

Cramer reveals JP Morgan Healthcare Conference winners and losers

2018-01-16 cnbc
Of all the major conferences that kicked off 2018 — from the ICR confab to the tech-laden CES — the J.P. Morgan Healthcare Conference was the most important for CNBC's Jim Cramer. (297-0)

AstraZeneca's Lynparza Label Now Includes Breast Cancer

2018-01-15 zacks
AstraZeneca, plc (AZN - Free Report) and partner Merck (MRK - Free Report) announced that the FDA has approved the supplemental New Drug Application (sNDA) for Lynparza seeking approval for label expansion in metastatic breast cancer. Lynparza is presently marketed for advanced ovarian cancer. (73-0)

Biotech Analysis Central Pharma News: Roche's MS Win, Aradigm FDA Panel Woes, AstraZeneca's Expanded Indication

2018-01-15 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. (85-0)

Clovis - Promise For 2018 Looks Good

2018-01-14 seekingalpha
After years of M&A interest and worries about product approval, Clovis has started to market Rucaparib in 2017, as the pick-up in sales is disappointing. (77-2)

ROTY Edition 1 Volume 67: Starting January On A Strong Note

2018-01-03 seekingalpha
ROTY had a solid December and January appears to be starting on a strong note as well. (107-1)

Biotech Beast Positions For 2018: A Rising Tide Lifts Some Boats More Than Others

2017-12-31 seekingalpha
While the dip in drug approvals which occurred in 2016 was rectified in 2017, there is still a deficit in M&A. (252-5)

Clovis Up More Than 50% in 2017: What's Driving the Stock?

2017-12-28 zacks
Shares of Clovis Oncology, Inc. (CLVS - Free Report) have been on a roll. This small biotech company is up 51.2% so far this year, outperforming the 3.5% increase registered by the industry during this period. (80-1)

Nexthera Capital Lp - All Holdings - 13F 13D 13G Filings - Fintel.io

2017-12-27 fintel.io
Nexthera Capital Lp has disclosed 38 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 388,737,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Nexthera Capital Lp's top holdings are SPDR S&P Biotech ETF (NYSE:XBI) , Seattle Genetics, Inc. (NASDAQ:SGEN) , Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) , Clovis Oncology, Inc. (254-2)

‘I Am Going to Die Without This’: Regulators Target a Health-Care Lifesaver - Bloomberg

2017-12-22 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (103-0)

Redmile Group, LLC - Current Holdings - Fintel.io

2017-12-19 fintel.io
Redmile Group, LLC has disclosed 64 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 1,160,076,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Redmile Group, LLC's top holdings are Array BioPharma, Inc. (NASDAQ:ARRY) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) , Puma Biotechnology Inc. (NASDAQ:PBYI) , Seattle Genetics, Inc. (358-2)

ROTY Edition 1 Volume 64: Several Key Updates And Trades

2017-12-19 seekingalpha
While performance for December continues to disappoint, we continue to position the ROTY model account for a profitable 2018. (471-1)

CUSIP: 189464100